Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 24 Nov 2025 for Aurinia Pharmaceuticals Inc., €37k. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Jeffrey Allen Bailey: trading record in brief
Jeffrey Allen Bailey (chief executive) discloses dealings in 2 companies, chiefly Biodelivery Sciences International Inc and Aurinia Pharmaceuticals Inc. Over a trading history stretching from 6 August 2021 to 21 November 2025, the count stands at 7 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The record was last updated on 24 November 2025 with a share grant (€37k) in Aurinia Pharmaceuticals Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Jeffrey Allen Bailey
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations7 total
2,716 shares@ US$15.68100.0% of flowCommon SharesSEC:0001600620-25-000110:0
12,135 shares0Common SharesSEC:0001600620-24-000120:0
17,913 sharesCommon StockSEC:0001600620-24-000116:0
105,133 shares0Common StockSEC:0001103021-22-000065:0
5,333 shares0Common StockSEC:0001103021-22-000053:0
53,333 shares0Common StockSEC:0001628280-21-022261:0
5,567 shares0Common StockSEC:0001103021-21-000076:0
7 of 7 declarations
